Metastatic Endometrial Carcinoma
Information
- Disease name
- Metastatic Endometrial Carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03120624 | Active, not recruiting | Phase 1 | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer | September 15, 2017 | July 15, 2024 |
| NCT03367741 | Active, not recruiting | Phase 2 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | April 16, 2018 | December 31, 2024 |
| NCT03508570 | Active, not recruiting | Phase 1 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | September 21, 2018 | April 30, 2025 |
| NCT05092373 | Recruiting | Phase 1 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | April 29, 2022 | September 1, 2026 |
| NCT05269381 | Recruiting | Phase 1/Phase 2 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | March 31, 2022 | February 24, 2026 |
| NCT05691504 | Recruiting | Phase 1 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | September 14, 2023 | June 1, 2026 |
| NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
| NCT06349642 | Recruiting | Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform | April 24, 2024 | May 2027 |